An update on disease biomarkers for Hodgkin lymphoma

被引：4

作者：

Cirillo, Melita ^{[1
,2
,3
,4
,5
]}

Borchmann, Sven ^{[1
,2
,3
,6
]}

机构：

[1] Univ Cologne, Fac Med, Cologne, Germany

[2] Univ Cologne, GHSG, Univ Hosp Cologne, Dept Internal Med 1, Cologne, Germany

[3] Univ Cologne, Ctr Mol Med, Univ Hosp Cologne, Cologne, Germany

[4] Royal Perth Hosp, Dept Hematol, Perth, WA, Australia

[5] Univ Western Australia, Perth, WA, Australia

[6] Univ Cologne, Else Kroner Forsch Kolleg Clonal Evolut Canc, Univ Hosp Cologne, Cologne, Germany

来源：

EXPERT REVIEW OF HEMATOLOGY | 2020年 / 13卷 / 05期

关键词：

Hodgkin lymphoma; prognosis; treatment; chemotherapy; TARC; cell free DNA; tumor microenvironment; pet scan; metabolic tumor volume; genotyping; POSITRON-EMISSION-TOMOGRAPHY; RESPONSE-ADAPTED THERAPY; METABOLIC TUMOR VOLUME; INTERNATIONAL PROGNOSTIC SCORE; STEM-CELL TRANSPLANTATION; REED-STERNBERG CELLS; FREE CIRCULATING DNA; SERUM TARC LEVELS; BARR-VIRUS-DNA; INTERGROUP TRIAL;

D O I：

10.1080/17474086.2020.1746183

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction: Hodgkin Lymphoma (HL) carries an overall excellent prognosis for young patients treated with multimodal therapy. Predicting an individual patient's prognosis is currently heavily dependent on imaging modalities such as Positron Emission Tomography (PET). Areas covered: Potential biomarkers from serum, tissue, circulating nucleic acids and non-tumor derived cells have all been reported to be of prognostic relevance in HL. We review a range of these biomarkers and discuss the integration of new biomarkers into individualized patient care. Expert opinion: Better prognostic markers are needed to predict an individuals response to HL therapy. Interim PET-scan improves the ability to predict long-term treatment responders. However, it is our opinion that supplementation of PET results with additional biomarkers (including circulating tumor DNA, protein biomarkers, tissue genotyping and metabolic tumor volume) are likely to improve risk stratification for future patients with HL.

引用

页码：481 / 488

页数：8

共 72 条

[51] Kinetics of Circulating Plasma Cell-Free DNA in Paediatric Classical Hodgkin Lymphoma
Primerano, Simona
Burnelli, Roberta
Carraro, Elisa
Pillon, Marta
Elia, Caterina
Farruggia, Piero
Sala, Alessandra
Vinti, Luciana
Buffardi, Salvatore
Basso, Giuseppe
Mascarin, Maurizio
Mussolin, Lara
[J]. JOURNAL OF CANCER, 2016, 7 (04): : 364 - 366
[52] Positron Emission Tomography-Based Assessment of Metabolic Tumor Volume Predicts Survival after Autologous Hematopoietic Cell Transplantation for Hodgkin Lymphoma
Prochazka, Vit
Gawande, Rakhee S.
Cayci, Zuzan
Froelich, Jerry W.
Cao, Qing
Wilke, Chris
Dusenbery, Kathryn
Weisdorf, Daniel J.
Bachanova, Veronika
[J]. BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2018, 24 (01) : 64 - 70
[53] Results of a Trial of PET-Directed Therapy for Early-Stage Hodgkin's Lymphoma
Radford, John
Illidge, Tim
Counsell, Nicholas
Hancock, Barry
Pettengell, Ruth
Johnson, Peter
Wimperis, Jennie
Culligan, Dominic
Popova, Bilyana
Smith, Paul
McMillan, Andrew
Brownell, Alison
Kruger, Anton
Lister, Andrew
Hoskin, Peter
O'Doherty, Michael
Barrington, Sally
[J]. NEW ENGLAND JOURNAL OF MEDICINE, 2015, 372 (17) : 1598 - 1607
[54] High-dose chemotherapy followed by autologous stem cell transplantation for patients with relapsed/refractory Hodgkin lymphoma
Rancea, Michaela
Monsef, Ina
von Tresckow, Bastian
Engert, Andreas
Skoetz, Nicole
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2013, (06):
[55] PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome
Roemer, Margaretha G. M.
Advani, Ranjana H.
Ligon, Azra H.
Natkunam, Yasodha
Redd, Robert A.
Homer, Heather
Connelly, Courtney F.
Sun, Heather H.
Daadi, Sarah E.
Freeman, Gordon J.
Armand, Philippe
Chapuy, Bjoern
de Jong, Daphne
Hoppe, Richard T.
Neuberg, Donna S.
Rodig, Scott J.
Shipp, Margaret A.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (23) : 2690 - +
[56] Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment
Sasse, Stephanie
Reddemann, Katharina
Diepstra, Arjan
Oschlies, Ilske
Schnitter, Antje
Borchmann, Sven
Engert, Andreas
Borchmann, Peter
Klapper, Wolfram
[J]. HAEMATOLOGICA, 2019, 104 (01) : E21 - E24
[57] Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials
Sasse, Stephanie
Broeckelmann, Paul J.
Goergen, Helen
Pluetschow, Annette
Mueller, Horst
Kreissl, Stefanie
Buerkle, Carolin
Borchmann, Sven
Fuchs, Michael
Borchmann, Peter
Diehl, Volker
Engert, Andreas
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (18) : 1999 - +
[58] Baseline serum TARC levels predict therapy outcome in patients with Hodgkin lymphoma
Sauer, Maike
Pluetschow, Annette
Jachimowicz, Ron D.
Kleefisch, Dominik
Reiners, Katrin S.
Ponader, Sabine
Engert, Andreas
von Strandmann, Elke Pogge
[J]. AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (02) : 113 - 115
[59] Gene Expression-Based Model Using Formalin-Fixed Paraffin-Embedded Biopsies Predicts Overall Survival in Advanced-Stage Classical Hodgkin Lymphoma
Scott, David W.
Chan, Fong Chun
Hong, Fangxin
Rogic, Sanja
Tan, King L.
Meissner, Barbara
Ben-Neriah, Susana
Boyle, Merrill
Kridel, Robert
Telenius, Adele
Woolcock, Bruce W.
Farinha, Pedro
Fisher, Richard I.
Rimsza, Lisa M.
Bartlett, Nancy L.
Cheson, Bruce D.
Shepherd, Lois E.
Advani, Ranjana H.
Connors, Joseph M.
Kahl, Brad S.
Gordon, Leo I.
Horning, Sandra J.
Steidl, Christian
Gascoyne, Randy D.
[J]. JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (06) : 692 - 700
[60] Comparison of first-line chemotherapy including escalated BEACOPP versus chemotherapy including ABVD for people with early unfavourable or advanced stage Hodgkin lymphoma
Skoetz, Nicole
Will, Andrea
Monsef, Ina
Brillant, Corinne
Engert, Andreas
von Tresckow, Bastian
[J]. COCHRANE DATABASE OF SYSTEMATIC REVIEWS, 2017, (05):

← 1 2 3 4 5 6 7 8 →